Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 10/20 | 0.42 |
| ▸ | CPT2 | P23786 | 5/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17045003 | 0.87 | HCRTR1 (0.40) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL16188339 | 0.85 | KCNH2 (0.41) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL30065501 | 0.84 | KCNH2 (0.47) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL20952286 | 0.84 | KCNH2 (0.47) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL474879 | 0.84 | KCNH2 (0.47) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL894772 | 0.83 | KCNH2 (0.39) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL17044953 | 0.82 | HCRTR1 (0.49) | HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL16309223 | 0.82 | HCRTR1 (0.49) | HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL20952517 | 0.81 | KCNH2 (0.43) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 | |
| SCHEMBL10173660 | 0.81 | KCNH2 (0.43) | CPT1ACPT2HCRTR1HCRTR2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CPT1A 154/4885CPT2 1708/4885HCRTR1 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.